The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).
 
David Barbie
Stock and Other Ownership Interests - Medzown; Xsphera Biosciences
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Gilead Sciences; Synthekine
Consulting or Advisory Role - Nerviano Medical Sciences; Qiagen/N of One
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Gilead Sciences; Novartis
Patents, Royalties, Other Intellectual Property - DFCI patents on microfluidic culture and analysis of organotypic tumor spheroids
 
Mingchao Xie
Employment - AstraZeneca
 
Maria Broggi
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Novartis
Travel, Accommodations, Expenses - AstraZeneca
 
Ying Cheng
No Relationships to Disclose
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); ModeX Therapeutics (Inst); Novartis (Inst); Novocure (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Amgen; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; BMS; Boehringer Ingelheim; Bridgebio; CJ bioscience; Cyrus therapeutics; Cyrus therapeutics; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Guardant Health; Harpoon Therapeutics; J INTS Bio; Janssen; Kanaph Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Therapex Co., Ltd; Yuhan
Research Funding - AstraZeneca; Champions Oncology; CJ bioscience; Cyrus Therapeutics; Dong-A ST; GI Innovation; ImmuneOncia; J Ints Bio; Janssen; MSD; Therapex; Vertical Bio AG; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Jian Fang
No Relationships to Disclose
 
Yuanbin Chen
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Pfizer; Guardant Health; Jazz Pharmaceuticals; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Guardant Health; Jazz Pharmaceuticals; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Merck (Inst)
Expert Testimony - AstraZeneca; Takeda
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Johnson & Johnson/Janssen; Kyowa Kirin International; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst)
 
Ki Hyeong Lee
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson/Janssen; Lilly; MSD; Pfizer; Takeda; Yuhan
Research Funding - Merck
(OPTIONAL) Uncompensated Relationships - Roche
 
Qiming Wang
No Relationships to Disclose
 
Alejandro Navarro
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Hengenix Biotech; Janssen; MedSIR; Merck Sharp & Dohme; Oryzon Genomics; Pfizer
Travel, Accommodations, Expenses - Janssen; Pfizer; Roche; Takeda
Other Relationship - Adium; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eczacibasi; IPSEN (Inst); Merck Sharp & Dohme (Inst); PharmaMar (Inst); Regeneron; Roche; Roche (Inst); Takeda; Tecnofarma
 
Eva Lotte Buchmeier
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen
Research Funding - AstraZeneca; Janssen
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Other Relationship - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
 
Mustafa Özgüroglu
Honoraria - Astellas Pharma; Janssen Oncology (Inst); Novartis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; MSD Oncology
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Christine Hann
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Janssen Oncology; Puma Biotechnology
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst)
 
Jocelyn Chen
Employment - AstraZeneca
 
Wei-Chu Lai
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yashaswi Shrestha
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Suresh Senan
Honoraria - AstraZeneca; MSD
Consulting or Advisory Role - AstraZeneca; Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Varian Medical Systems (Inst)